Anavex Presents Positive Results for Both ANAVEX 2-73 and ANAVEX 3-71 in Alzheimer’s Models at 2015 AD/PD™ Conference

ANAVEX 2-73 strong reversal of memory impairment in Alzheimer’s disease model ANAVEX 3-71 strong reversal of synaptic loss in Alzheimer’s disease models NEW YORK, NY – March 23, 2015 – Anavex Life Sciences Corp. (“Anavex” or the “Company”) (OTCQX: AVXL), a clinical-stage biopharmaceutical company developing drug candidates to treat Alzheimer’s and other central nervous system…

Anavex Appoints Epilepsy and Clinical Trial Methodology Expert to Scientific Advisory Board

NEW YORK, NY –March 12, 2015 – Anavex Life Sciences Corp. (“Anavex” or the “Company”) (OTCQX: AVXL), a clinical-stage biopharmaceutical company developing drug candidates to treat Alzheimer’s disease, other central nervous system (CNS) diseases, pain and various types of cancer, today announced the appointment of Jacqueline French, MD, FAAN, to the Company’s Scientific Advisory Board.…

Anavex to Present at Sigma-1 Receptors Symposium

NEW YORK, NY – March 10, 2015 – Anavex Life Sciences Corp. (“Anavex” or the “Company”) (OTCQX: AVXL) a clinical-stage biopharmaceutical company developing drug candidates to treat Alzheimer’s disease, other central nervous system (CNS) diseases, pain and various types of cancer, today announced that Christopher U. Missling, PhD, President and Chief Executive Officer, will present…

Anavex Appoints Scientific Advisory Board Member with Expertise in Protein Misfolding Neurodegenerative Diseases

NEW YORK, NY –March 5, 2015 – Anavex Life Sciences Corp. (“Anavex” or the “Company”) (OTCQX: AVXL), a clinical-stage biopharmaceutical company developing drug candidates to treat Alzheimer’s disease, other central nervous system (CNS) diseases, pain and various types of cancer, today announced the appointment of Corinne Lasmézas, DVM, PhD, to the Company’s Scientific Advisory Board.…